BBR Partners LLC Sells 50,000 Shares of OmniAb, Inc. (NASDAQ:OABI)

BBR Partners LLC lessened its stake in shares of OmniAb, Inc. (NASDAQ:OABI) by 71.4% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 20,000 shares of the company’s stock after selling 50,000 shares during the quarter. BBR Partners LLC’s holdings in OmniAb were worth $71,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in OABI. Murchinson Ltd. purchased a new stake in OmniAb during the third quarter valued at $4,230,000. Barclays PLC increased its position in shares of OmniAb by 321.5% during the 3rd quarter. Barclays PLC now owns 143,215 shares of the company’s stock valued at $606,000 after purchasing an additional 109,236 shares during the last quarter. Atria Investments Inc bought a new position in shares of OmniAb in the 3rd quarter worth approximately $148,000. State Street Corp lifted its stake in shares of OmniAb by 1.7% in the 3rd quarter. State Street Corp now owns 2,031,676 shares of the company’s stock worth $8,594,000 after purchasing an additional 34,654 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of OmniAb by 4.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 819,708 shares of the company’s stock worth $2,902,000 after buying an additional 32,186 shares during the last quarter. 72.08% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the stock. Benchmark reiterated a “buy” rating and issued a $8.00 price target on shares of OmniAb in a research report on Thursday, November 14th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of OmniAb in a report on Thursday, November 14th.

Insider Activity

In related news, CFO Kurt A. Gustafson sold 7,255 shares of the stock in a transaction dated Wednesday, February 19th. The stock was sold at an average price of $3.67, for a total transaction of $26,625.85. Following the completion of the sale, the chief financial officer now owns 206,211 shares in the company, valued at approximately $756,794.37. This trade represents a 3.40 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Charles S. Berkman sold 25,489 shares of OmniAb stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $3.24, for a total value of $82,584.36. Following the sale, the insider now directly owns 343,190 shares in the company, valued at $1,111,935.60. This trade represents a 6.91 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 112,260 shares of company stock worth $376,601 in the last three months. Company insiders own 8.60% of the company’s stock.

OmniAb Price Performance

Shares of NASDAQ:OABI opened at $3.40 on Friday. The company has a market capitalization of $480.13 million, a P/E ratio of -5.48 and a beta of -0.14. OmniAb, Inc. has a 1-year low of $3.10 and a 1-year high of $5.72. The firm’s 50 day simple moving average is $3.46 and its two-hundred day simple moving average is $3.86.

OmniAb Company Profile

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.